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CASE REPORTS
ABSTRACT
Background: Celiac disease is described in association with 
several autoimmune diseases, but rarely with myasthenia gravis. 
Case report: We describe the case of a 31-year-old white 
woman with celiac disease who presented manifestations related to 
a hyperactive immune system, including macroamylasemia, false-
positive anti-HCV, positive antinuclear antibody, and Raynaud’s 
phenomenon. The introduction of a gluten-free diet (GFD) resolved 
these features, but myasthenia gravis (MG) symptoms unexpectedly 
occurred on that occasion. 
Discussion: The role of a GFD in the course of autoimmune 
diseases has been studied and improvement has been reported 
in many diseases. However, there is no consensus in the litera-
ture regarding the course of neurological disorders associated with 
celiac disease. In the present case, a GFD did not prevent the 
appearance of symptoms related to myasthenia gravis. There are 
few reports on the association of celiac disease with myasthenia 
gravis and therefore little is known about the course and time of 
onset of myasthenia in celiac patients. The present case increases 
the knowledge about this unusual autoimmune neurological disease 
associated with celiac disease.
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INTRODUCTION
Celiac disease (CD) is described in association with sev-
eral autoimmune diseases (1) and neurological disorders, 
and up to 10% of CD patients develop neurological com-
plications (2). Myasthenia gravis (MG) is an autoimmune 
neuromuscular disorder that is rarely described in patients 
with CD (3). We report the case of a patient with CD who 
presented manifestations related to a hyperactive immune 
system, including macroamylasemia, false-positive anti-
HCV, positive antinuclear antibody, Raynaud’s phenom-
enon, and MG. The administration of a gluten-free diet 
(GFD) caused rapid resolution of diarrhea and regression 
of immune events, but symptoms of MG unexpectedly 
occurred on that occasion.
CASE REPORT
A 31-year-old woman was seen at our gastroenterology 
service with a 9-year history of intermittent diarrhea, asso-
ciated with abdominal pain and weight loss of 12 kg. Previ-
ous laboratory investigation at another service had shown 
persistent hyperamylasemia and anemia. The patient had a 
history of an episode of Raynaud’s phenomenon associated 
with intensification of diarrhea one year earlier and report-
ed worsening of diarrhea in the last 4 months, as well as 
hypotension, hyporexia and muscle weakness. 
Upper gastrointestinal endoscopy showed erosive and 
nodular bulboduodenitis and the duodenal biopsy findings 
included moderate to severe chronic erosive duodenitis and 
villus atrophy. Anti-tissue transglutaminase IgA autoanti-
bodies were positive. The patient exhibited no symptoms 
consistent with acute pancreatitis, and other non-pancreatic 
causes of hyperamylasemia in CD patients were therefore 
investigated. Measurement of serum and urine amylase 
levels showed low amylase clearance, consistent with mac-
roamylasemia. The results of laboratory tests included pos-
itive antinuclear antibody (1/160, coarse reticular speckled 
pattern) and positive anti-HCV. PCR for virus C RNA and 
anti-dsDNA, anti-RNP and anti-SM were negative. Nail-
fold capillaroscopy was normal.
After the diagnosis of CD, a GFD was introduced and 
the patient exhibited resolution of diarrhea and weight 
loss. Anti-transglutaminase antibodies and anti-HCV sub-
sequently became negative and amylasemia was normal-
ized (Table I).
During follow-up, about one year after the introduc-
tion of the GFD, the patient developed asthenia, diplopia, 
headache, and worsening of weakness in the absence of 
associated gastrointestinal symptoms. Neurological exam-
ination showed rapid muscle fatigue on repetitive exer-
cise. Limb muscle strength was reduced after prolonged 
physical exercise and palpebral ptosis on sustained upward 
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gaze was observed. Diplopia occurred after eye lateral-
ization for 20 seconds. Reflexes and sensory testing were 
normal. Electroneuromyography revealed diffuse myopa-
thic changes consistent with MG. Acetylcholine receptor 
antibodies were positive (4.71 nmol/L, reference: positive 
> 0.5 nmol/L). Computed tomography showed no evidence 
of thymoma. The diagnosis of MG was made and treatment 
with prednisone and azathioprine was initiated.
DISCUSSION
Celiac disease is an autoimmune T cell-mediated disor-
der triggered by the ingestion of gluten in genetically pre-
disposed individuals. More than 99% of patients express 
HLA DQ2 or DQ8 (2). The prevalence of autoimmune dis-
eases is higher in patients with CD when compared to the 
healthy control population. The cumulative risk of autoim-
mune disease in patients with CD is 8% at age 15 and 16% 
at age 30. Exposure to gluten seems to contribute to the 
emergence of autoimmunity and patients who adhere to a 
GFD have a lower risk of developing autoimmune diseases 
(1). The observation of normalization of immune events in 
the present case after introduction of the GFD supports this 
hypothesis. However, even within this context, the patient 
developed symptoms related to MG.
Macroamylasemia is a benign condition caused by 
circulating macroamylase complexes of pancreatic or 
salivary amylase bound to plasma proteins, which can-
not be cleared by the renal glomeruli. In most cases, the 
macromolecular amylase represents a complex of normal 
amylase and either immunoglobulin A or G, and may be a 
specific antigen-antibody complex (4). There are reports 
of CD associated with macroamylasemia, with disappear-
ance of this macroenzyme after the introduction of a GFD 
(5,6), as observed in the present patient. The understand-
ing of this event could prevent patients from being sub-
mitted to extensive investigation of pancreatic diseases. 
The frequency of macroamylasemia has been shown to 
be higher among patients newly diagnosed with CD than 
in those receiving a GFD and in these two populations 
compared to controls without CD (7), a fact demonstrating 
the role of gluten in the occurrence of this disorder. With 
respect to the association of CD with Raynaud’s phenom-
enon, few data are available in literature. The rationale 
for this association could be the common autoimmune 
pathogenetic background of both disorders. Moreover, the 
strong immunoinflammatory activation observed in active 
CD that triggers the chronic release of several cytokines 
endowed with vasoactive properties (interferon-gamma 
and interleukin-2, -4, -10) might affect arterial regulation 
in predisposed patients (8). There are reports indicating a 
reduction in Raynaud’s phenomenon after the introduction 
of a GFD and vitamin reposition (9,10).
Little is known about the association of CD with myas-
thenia gravis. Both conditions are T cell-mediated auto-
immune diseases in which tissue transglutaminase and 
nicotinic acetylcholine receptors are the target antigens 
of the immune attack, respectively (2). The association 
between CD and myasthenia gravis could be coinciden-
tal, but available evidence suggests that these two distinct 
immune-mediated disorders occur together more frequent-
ly than is currently appreciated. Similar human leukocyte 
antigen types (HLA-DR3, -DQ2,-DQ8) seem to predispose 
to both MG and CD (3,11). Some serological surveys have 
investigated the concurrence of antibodies present in the 
two diseases, with no expressive results (2,3). We found 
three studies in the literature reporting the association of 
these two diseases in which the diagnosis of CD preceded 
symptoms of MG (3,12,13), and one case in which subclin-
ical CD was diagnosed after serological screening of tTG 
and EMA in patients with myasthenia gravis, confirmed 
by duodenal biopsy (3) (Table II). 
There are reports of the occurrence of MG even after 
the introduction of a GFD in patients with CD (3,12). The 
role of a GFD in the course of autoimmune diseases has 
been studied, but there is no consensus in the literature 
regarding the course of neurological disorders associated 
with CD. These disorders sometimes become symptomatic 
after long periods of exclusion of gluten from the diet (14), 
as observed in our patient. Muscle weakness in patients 
with malabsorption might be related to malnutrition or 
electrolyte disorders. In the present case, aggravation of 
this symptom was observed after the restrictive diet and 
in the absence of intestinal symptoms. The diagnosis of 
accompanying MG may be delayed if weakness is ascribed 
to CD. The presence of motor weakness and diplopia in 
treated CD may be a clue to occult myasthenia gravis (11). 
Table I. Laboratory tests prior to the diagnosis of celiac disease and after the administration of a gluten-free diet 
Laboratory test Prior to diagnosis After gluten-free diet
Hemoglobin 11.8 g/dL 14 g/dL
Serum albumin 2.3 g/dL 4.2 g/dL
Serum amylase 768 U/L 80 U/L
Transglutaminase antibody 159 U < 18 U
Anti-HCV Positive* Negative
*Negative PCR for virus C RNA. 
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Table II. Characteristics of reported cases of myasthenia gravis associated to celiac disease
Case Gender Age First diagnosed GFD Antibodies Duodenal biopsy Autoimmune associations
1 (3) Male 40 CD Yes tTG, AChR Yes No
2 (3)1 Female 16 MG - tTG/EMA, AChR Yes No
3 (12) Female 22 CD Yes EMA, AChR Yes No
4 (13) Female 51 CD - All negative - Sjögren, hypothyroidism
52 Female 31 CD Yes tTG, AChR Yes Raynaud, macroamylasemia
1Subclinical celiac disease. 2Current case. CD: Celiac disease; MG: Myasthenia gravis; tTG: Tissue transglutaminase antibody; EMA: Endomysial antibody; AChR: acetyl-
choline receptor antibody; GFD: Gluten-free diet.
